Introduction
Bryostatin, which belongs to a group of macrocyclic lactones isolated from a marine bryozoan, has shown potent antineoplastic properties in vitro and in vivo. 1 Bryostatin has definitive activity against a variety of myeloid and lymphoid malignancies with a novel mechanism of action. 2, 3 The antitumor effects of bryostatin are believed to be mediated by protein kinase C (PKC) activation, 4 as a consequence of binding to the regulatory domain of PKC and inducing PKC translocation, activation and eventually downregulation of PKC expression. 5, 6 Studies on bryostatin-induced cell differentiation have demonstrated that its function is variable and ranged from no effect, partial effect to full stimulation on several fresh human leukemia cell samples and different sources of HL60 cell lines in vitro. 2 Unlike phorbol 12-myristate 13-acetate (PMA), bryostatin does not act as a tumor promoter when applied to mouse skin, 7 but mimics many of the effects of PMA in its ability to act as mitogens for multiple cellular functions. 8 Bryostatin 9 shows a strong antitumor activity on a series of tested human tumor cells. homeostasis 11 and regulating the immune system. 12 It has been shown to induce the differentiation of several myelocytic leukemia cell lines. [13] [14] [15] [16] Numerous leukemia cell lines have been studied in an effort to understand the mechanisms of tumor cell differentiation and proliferation. Induction of leukemia cell differentiation in vitro by drugs is related to the clinical remission process.
NB4 cells, an acute promyelocytic leukemia (APL) cell line, carry a specific cytogenetic mutation, t (15;17) . This abnormal translocation creates a hybrid gene termed PML-RAR␣ gene and its product, mutant PML-RAR␣ receptor, plays a dominant-negative role blocking the NB4 cells along their differentiation pathway. 17 18,20 Recently, we reported that the combination of PMA and 1␣,25(OH) 2 D 3 not only promoted the morphological differentiation of NB4 cells into monocyte/macrophage-like cells but also synergistically stimulated the alkaline phosphatase (ALP) expression which is a characteristic of mature neutrophils. 20 The aim of the present study was to investigate the combination effect of bryostatin-1 and 1␣,25(OH) 2 D 3 on NB4 cell differentiation as measured by ALP induction and a series of morphological parameters. The rationale of this study is to replace PMA with bryostatin-1 because PMA is a tumor promoter, which limits its clinical application. Bryostatin-1 is a natural product antitumor agent and has currently undergone a phase II clinical trial in humans. Here, we present data demonstrating that bryostatin-1 acts synergistically with 1␣,25(OH) 2 D 3 to significantly increase the NB4 cell differentiation, and as well to block cell proliferation. This combination treatment may become potentially useful as an alternative therapy for APL patients.
Materials and methods

Chemicals
DMEM/F12 Ham medium, fetal calf serum (FCS) and other tissue culture reagents were purchased from Sigma (St Louis, MO, USA). 1␣,25(OH) 2 D 3 was the gift of Dr MR Uskokovic (Hoffmann-La Roche, Nutley, NJ, USA). Bryostatin-1 was purchased from LC Laboratories (Woburn, MA, USA). Naphthol AS-TR phosphate and diazonium fast blue RR salt were purchased from Sigma. All other reagents were obtained from standard laboratory suppliers and were of the highest grade.
Cell cultures
NB4 cells were obtained from Dr KA Meckling-Gill (Guelph, Ontario, Canada), which were originally isolated from a patient with acute promyelocytic leukemia (APL) by Dr Michel Lanotte at the Hospital Saint-Louis (Unite INSERM 301, Paris, France). 21 The cell line was characterized by a translocation involving chromosomes 15 and 17, which is typical of the classical form of APL-M3 in the French-American-British (FAB) classification. NB4 cells were cultured in DMEM/F12 Ham medium supplemented with 10% fetal calf serum and 5% CO 2 balanced air and were routinely passaged as suspension cultures and only passages 8 to 20 were used for each experiment. Cell growth and viability were assessed using the trypan blue dye method and more than 95% of the cells showed viability in the experimental culture conditions. 1␣,25(OH) 2 D 3 and PMA were initially dissolved in ethanol at 10 −4 M. The final concentration of ethanol in all experiments was less than 0.1%. An equivalent amount of ethanol as vehicle was included in the control.
Cell number and adherence
To examine the effects of 1␣,25(OH) 2 D 3 and PMA on cell growth and adherence, 1 ml aliquots of cell suspension at 2 × 10 4 cells/ml were seeded in a 24-well plate. Cells were treated with vehicle, 1␣,25(OH) 2 D 3 , bryostatin-1, PMA and the combination of either bryostatin-1 or PMA with 1␣,25(OH) 2 D 3 in DMEM/F12 Ham medium supplemented with 10% charcoal-stripped fetal bovine serum. After every 24-h interval, the cells in suspension were collected and the cells that had adhered were trypsinized from each well with 1 × trypsin-EDTA solution (Sigma). Both suspension and adherent cells were counted using a hemocytometer to determine the percentage of the cell adherence. After combining both fractions, an aliquot of 100 l of cell suspension was removed to determine the total cell numbers with a hemocytometer. Adherence was expressed as the percentage of the adherent cells vs total cells.
Phagocytosis
The method developed for studying phagocytosis is described by Bhatia et al. 22 Briefly, latex beads (3 m, Sigma) were added to cell cultures for 5 h at 37°C after 72 h of treatment with the factors. Cells were centrifuged at 125 g for 5 min and washed with cold phosphate buffered saline (PBS) to remove the free beads. The washing procedure was repeated four times at room temperature. At the end of the experiment, the cells were further stained for ALP and fixed in 10% formalin solution; the cells that had engulfed the beads were counted under the light microscope.
ALP (EC 3.1.3.1) assay
The cellular ALP activity was measured in a 1% Triton X-100 extract of the cells. Briefly, cells were plated at a density of 10 4 cell/ml and cultured in 24-well plates in DMEM/F12 Ham medium supplemented with 10% charcoal-stripped fetal bovine serum. After 72 h of treatment, the cells were collected, centrifuged and washed once with PBS saline buffer. Subsequently, the cells were extracted with 0.5 ml of 0.1% Triton X-100 and stored in a −4°C refrigerator. The biochemical determination of ALP activity was performed using an ALP assay kit (Sigma). The ALP activity in the extract was determined by measuring the rate of hydrolysis of p-nitrophenyl phosphate to p-nitrophenol that has a yellow color with maximum absorbance at 410 nm. The reaction was initiated by the addition of cell extract (50 l) to the ALP substrate and the mixture was incubated at room temperature for 2 h. The absorbance was determined with a BioRad Microwell Plate Reader (Bio-Rad, Hercules, CA, USA). Protein concentration of the cell extracts were determined using a protein assay kit (BioRad) with bovine serum albumin as a standard. The specific ALP activity was calculated as milliunits per milligram of protein and reported as percentage of vehicle-treated control. A milliunit of ALP activity was defined as the amount of enzyme needed to catalyze the production of 1 nanomole pnitrophenol from p-nitrophenyl phosphate per min at room temperature.
Cytochemical staining for ALP
The histochemical localization of ALP activity in cells was determined by the azo dye method. 23 The substrate was ␣-naphthol-AS-TR phosphate and the diazonium was fast blue RR salt. The cells were washed once with ALP staining buffer containing 50 mM Tris-HCl, pH 8.6, 100 mM NaCl, 5 mM KCl, 1 mM CaCl 2 and 1 mM MgCl 2 and then incubated with 10 ml of ALP staining buffer containing 8 mg ALP substrate and 1 mg of azo dye in a total volume of 10 ml for 30 min at 37°C. Then, the cells were further fixed in 10% formalin of PBS buffer, the ALP positive staining cells were counted and photographed with an Olympus microscope (Narishige Scientific Lab, Tokyo, Japan).
Statistics
All results are expressed as mean ± s.d. A two-tail unpaired Student's t-test or a two-way analysis of variance (ANOVA) for multiple comparisons was used for statistical analysis. A difference between experimental groups was considered significant when the P value was Ͻ0.05 or Ͻ0.01.
Results
Time course effect of bryostatin-1, PMA and 1␣,25(OH) 2 D 3 on ALP expression and cell proliferation
The time course of NB4 cell differentiation and proliferation mediated by bryostatin-1, PMA and 1␣,25(OH) 2 D 3 is shown in Figure 1 . Treatment of NB4 cells individually with 5.6 nM bryostatin-1, 5.6 nM PMA or 10 nM 1␣,25(OH) 2 D 3 had little effect on ALP expression during a 5-day period (Figure 1a) . However, the simultaneous treatment of the cells with either bryostatin-1 or PMA in the presence of 1␣,25(OH) 2 D 3 significantly stimulated ALP induction. The highest ALP induction, seen at 72 h, was 3300 ± 310% or 4200 ± 380% over the control for the combination of 1␣,25(OH) 2 D 3 plus bryostatin-1 (P Ͻ 0.001) or PMA (P Ͻ 0.001), respectively.
The effect of bryostatin-1, PMA and 1␣,25(OH) 2 D 3 on NB4 cell proliferation was assessed by measuring cell number (Figure 1b) . Compared with control, 1␣,25(OH) 2 D 3 alone at 10 nM did not affect NB4 cell proliferation during a 5-day period. Both bryostatin-1 alone and PMA alone at 5.6 nM significantly decreased cell numbers from day 2 to day 5 (P Ͻ 0.001). The combination of bryostatin-1 with 
Morphological cell differentiation induced by bryostatin-1, PMA and 1␣,25(OH) 2 D 3
PMA alone can promote NB4 cell differentiation into monocyte/macrophage-like cells and when combined with 1␣,25(OH) 2 D 3 , it also induced NB4 cells to highly express ALP activity. 20 In the present studies, we further tested the effect of bryostatin-1 and 1␣,25(OH) 2 Figure 4B ). Bryostatin-1 alone induced cell adherence and phagocytosis by 20 ± 3% and 16 ± 2% at day 3, respectively (Table 1) . PMA alone stimulated the adherence and phagocytosis of NB4 cells by 37 ± 6% and 28 ± 5%, respectively (Table 1) . No ALP-positive staining cells are seen in both suspension and adherent cells of bryostatin-1 or PMA treatment groups ( Figure 4C and D) . Compared with individual agent treatment, the combination treatments of bryostatin-1 plus 1␣,25(OH) 2 D 3 or PMA plus 1␣,25(OH) 2 D 3 not only greatly increased cell adherence by 58 ± 6% and 64 ± 6%, respectively, but also greatly increased phagocytosis by 34 ± 4% and 43 ± 5% (Table 1) . Interestingly, the ALP-positive stained cells only appeared in the population of the adherent cells, but not the suspension cells, in both combination treatment groups ( Figure 4E and F) . Furthermore, our data clearly shows that both characteristics of ALP staining and phagocytosis can be seen in the same differentiated cells ( Figure 4E and F).
Discussion
We reported for the first time that in NB4 cells, the combination of PMA and 1␣,25(OH) 2 D 3 not only induced the appearance of a macrophage-like cell but also synergistically induced ALP expression. 20 A strong interaction between PMA and 1␣,25(OH) 2 D 3 on NB4 cell differentiation has also been described by others. 18 In the present study, we demonstrated that bryostatin-1, another native PKC activator, interacted with 1␣,25(OH) 2 D 3 to dramatically stimulate ALP activity and induce the differentiation of NB4 cells into monocyte/ macrophage-like cells. Since a single differentiated NB4 cell can have both characteristics of phagocytosis activity and ALP positive staining, 20 it is necessary to further study what mechanism is involved for NB4 cell differentiation. This is currently under investigation in our laboratory. A strong ALP induction induced by the combination of all-trans retinoic acid (ATRA) and cAMP was also reported after NB4 cells differentiated into granulocytes. 24 So it is uncertain what is the morphological significance between the monocyte/macrophages differentiation or granulocytes differentiation. However, a strong consistent ALP induction was seen in all combination treatments (PMA/1␣,25(OH) 2 D 3 , bryostatin-1/1␣,25(OH) 2 D 3 , and ATRA/cAMP) regardless of cell morphological changes. Human ALP is a multilocus enzyme and has been widely accepted as a cell differentiation marker for a variety of cell lines, such as bone, intestine, placenta and neutrophils. Therefore, it is conceivable that ALP activity could also be used as a convenient marker to evaluate NB4 leukemia cell differentiation, which could be used to monitor an APL patient's response to therapy.
PMA is a known PKC activator and is not a naturally occurring compound. Bryostatin-1 is a native compound and an antitumor agent. It shares a number of important properties with PMA, especially on the binding and activation of PKC 25 and inducing phosphorylation of specific substrates. 26 In the present study, bryostatin-1 was found to act in the same way as PMA and synergistically interacted with 1␣,25(OH) 2 D 3 to induce NB4 cell differentiation, as well as block cell proliferation. Many effects of PMA are mediated by activation of PKC pathways. Although the combination of PMA and 1␣,25(OH) 2 D 3 strongly induces NB4 cell differentiation, PMA itself has limited clinical use due to its tumor promoting effect. Furthermore, both bryostatin-1 and PMA have also shown significant differences in their actions. Unlike PMA, bryostatin-1 is not a tumor promoter in the commonly used model systems, 7 and when applied with PMA, it actually antagonizes the PMA effects. 27 PMA has been known to be a potent agent for inducing monocyte/macrophage differentiation of many myeloid cells, such as HL60, THP-1 as well as NB4 cells. 18, 28 Bryostatin shows a varied differentiation effect on human leukemia cells. It stimulated the differentiation of several fresh isolated human leukemia cells with varying effect on HL60 cell differentiation. 2 These results suggest that bryostatin-1 has a potential therapeutic effect on the treatment of APL patients.
1␣,25(OH) 2 D 3 has also been widely used as a cell differentiation agent in myeloid cell lines and acts as a proliferation to differentiation switch. [29] [30] [31] [32] Under normal circumstances, 1␣,25(OH) 2 D 3 binds to its nuclear receptor (VDR) and this complex can further form a heterodimer with RXR. This heterodimer acts as an active transcription factor that transactivates 1␣,25(OH) 2 D 3 -related gene expression and eventually leads to cell differentiation. 1␣,25(OH) 2 D 3 alone had no effect on NB4 cell differentiation. 18, 20 The reason is that in the NB4 cells, differentiation is blocked at the promyelocytic stage because the fusion protein PML/RAR␣ plays a dominant negative role on the RAR␣-mediated cell maturation. 17, 33 The PML/RAR␣ protein can prevent both the binding of the VDR nuc to a target DNA sequence in vitro and inhibit 1␣,25(OH) 2 D 3 -dependent activation of VDRnuc-responsive reporter genes in transfected cells due to formation of nonproductive heterodimers with RXR so as to consequently inhibit NB4 cell differentiation. 34 The mechanism for 1␣,25(OH) 2 D 3 PMA or bryostatin-1 action on NB4 cell differentiation is currently under investigation in our laboratory. It has been demonstrated that 1␣,25(OH) 2 D 3 alone can directly activate PKC and increase VDR phosphorylation. 35, 36 PMA was reported to up-regulate VDR mRNA and the VDR protein levels in myeloid cells or non-myeloid cells by activation of PKC. 37, 38 Furthermore, it has been suggested that PKC down-regulation rather than activation by bryostatin or PMA plays a role in the differentiation of several cell lines. [39] [40] [41] The mechanism of PMA in combination with 1␣,25(OH) 2 D 3 has been extensively studied in many other cell lines because these cells have proven to be extremely sensitive to this combination treatment. In U937 lymphoma cells, cell differentiation induced by 1␣,25(OH) 2 D 3 and PMA was assumed to be dependent on PKC-mediated phosphorylation of VDR. 42 Activation of different PKC isoforms by 1␣,25(OH) 2 D 3 and PMA was also proposed as a mechanism in the differentiation of THP-1 leukemia cells and NB4 cells. 43, 44 We have already reported that in NB4 cells, mitogen-activated protein kinase is involved in 1␣,25(OH) 2 D 3 action. 45 Since the ALP activity is one manifestation of NB4 cell differentiation 20 and is greatly induced by the combination of bryostatin-1 and 1␣,25(OH) 2 D 3 , we postulate that there are probably two different signal transduction pathways involved in this NB4 cell differentiation. They are the membrane-mediated kinase cascade and the classical VDR pathway. The former may potentiate the classical 1␣,25(OH) 2 D 3 pathway by phosphorylation of VDR, the latter of which may involve ALP gene transactivation. These two different signal transduction pathways may be required for NB4 cells to resume both the differentiation into monocyte/macrophage-like cells and the expression of ALP activity.
In the presence of 1␣,25(OH) 2 D 3 , the ALP response of NB4 cells to bryostatin-1 was somewhat less than that obtained with a similar dose of PMA, which has been demonstrated in a number of other cell systems. 2 The reason for this was postulated to be a differential competition between bryostatin and PMA on activation of different PKC isozymes 41, 46, 47 or that PMA is not a native compound and cannot be hydrolyzed by in vivo enzyme system. 48 ATRA has been successfully used for the treatment of patients with APL disease and can lead to clinical remission. 49 However, long-term treatment of patients with ATRA may result in drug resistance. An approach to deal with this drug resistance is to develop another alternative drug treatment. Our current results suggest that bryostatin-1 combined with 1␣,25(OH) 2 D 3 might be used as a new therapeutic alteration to treat APL patients. Further studies will be necessary to determine the molecular mechanism(s) for the effect of bryostatin-1 combined with 1␣,25(OH) 2 D 3 .
